Crossmark

Fasting or Non-fasting Lipids for Atherosclerotic Cardiovascular Disease Risk Assessment and Treatment?

Crossref DOI link: https://doi.org/10.1007/s11883-018-0713-2

Published Online: 2018-02-17

Published Print: 2018-03

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Rahman, Faisal

Blumenthal, Roger S.

Jones, Steven R.

Martin, Seth S.

Gluckman, Tyler J.

Whelton, Seamus P.
License Information

Text and Data Mining valid from 2018-02-17
More Information

Article History

First Online: 17 February 2018

Compliance with Ethical Standards

:

: Faisal Rahman, Roger S. Blumenthal, Tyler J. Gluckman, and Seamus P. Whelton declare no conflict of interest. Steven R. Jones and Seth S. Martin are listed as co-inventors on a pending patent filed by Johns Hopkins University for novel LDL-C estimation. Seth S. Martin has served on scientific advisory boards for Quest Diagnostics, Sanofi-Regeneron, Amgen, and Akcea Therapeutics.

: This article does not contain any studies with human or animal subjects performed by any of the authors.